Understanding EMPA-REG OUTCOME

被引：74

作者：

Muskiet, Marcel H. A. ^{[1
]}

van Raalte, Daniel H. ^{[1
]}

van Bommel, Erik J. M. ^{[1
]}

Smits, Mark M. ^{[1
]}

Tonneijck, Lennart ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Ctr Diabet, NL-1081 HV Amsterdam, Netherlands

来源：

LANCET DIABETES & ENDOCRINOLOGY | 2015年 / 3卷 / 12期

关键词：

HYPERTENSION;

D O I：

10.1016/S2213-8587(15)00424-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：928 / 929

页数：2

共 7 条

[1] Getting to the heart of the matter in type 2 diabetes [J].

不详 .

LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (11) :827-827

[2] Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes [J].

Cherney, David Z. I. ;

Perkins, Bruce A. ;

Soleymanlou, Nima ;

Xiao, Fengxia ;

Zimpelmann, Joseph ;

Woerle, Hans-Juergen ;

Johansen, Odd E. ;

Broedl, Uli C. ;

von Eynatten, Maximilian ;

Burns, Kevin D. .

KIDNEY INTERNATIONAL, 2014, 86 (05) :1057-1058

[3] Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes [J].

Heerspink, H. J. Lambers ;

de Zeeuw, D. ;

Wie, L. ;

Leslie, B. ;

List, J. .

DIABETES OBESITY & METABOLISM, 2013, 15 (09) :853-862

[4] Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients [J].

Jamerson, Kenneth ;

Weber, Michael A. ;

Bakris, George L. ;

Dahlof, Bjorn ;

Pitt, Bertram ;

Shi, Victor ;

Hester, Allen ;

Gupte, Jitendra ;

Gatlin, Marjorie ;

Velazquez, Eric J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) :2417-2428

[5] Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets [J].

Jiang, Fan ;

Yang, Jianmin ;

Zhang, Yongtao ;

Dong, Mei ;

Wang, Shuangxi ;

Zhang, Qunye ;

Liu, Fang Fang ;

Zhang, Kai ;

Zhang, Cheng .

NATURE REVIEWS CARDIOLOGY, 2014, 11 (07) :413-426

[6] Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Lindholm, LH ;

Ibsen, H ;

Dahlöf, B ;

Devereux, RB ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Julius, S ;

Kjeldsen, SE ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H ;

Aurup, P ;

Edelman, J ;

Snapinn, S .

LANCET, 2002, 359 (9311) :1004-1010

[7] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [J].

Zinman, Bernard ;

Wanner, Christoph ;

Lachin, John M. ;

Fitchett, David ;

Bluhmki, Erich ;

Hantel, Stefan ;

Mattheus, Michaela ;

Devins, Theresa ;

Johansen, Odd Erik ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Inzucchi, Silvio E. ;

Aizenberg, D. ;

Ulla, M. ;

Waitman, J. ;

De Loredo, L. ;

Farias, J. ;

Fideleff, H. ;

Lagrutta, M. ;

Maldonado, N. ;

Colombo, H. ;

Ferre Pacora, F. ;

Wasserman, A. ;

Maffei, L. ;

Lehman, R. ;

Selvanayagam, J. ;

d'Emden, M. ;

Fasching, P. ;

Paulweber, B. ;

Toplak, H. ;

Luger, A. ;

Drexel, H. ;

Prager, R. ;

Schnack, C. ;

Schernthaner, G. ;

Fliesser-Goerzer, E. ;

Kaser, S. ;

Scheen, A. ;

Van Gaal, L. ;

Hollanders, G. ;

Kockaerts, Y. ;

Capiau, L. ;

Chachati, A. ;

Persu, A. ;

Hermans, M. ;

Vantroyen, D. ;

Vercammen, C. ;

Van de Borne, P. ;

Mathieu, C. ;

Benhalima, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22) :2117-2128

← 1 →